Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Megamerger Dealzapoppin Poll
You can’t tell the players without a scorecard, especially in biopharma. This week alone, AstraZeneca reportedly turned down a £60 billion ($101 billion) offer from Pfizer, while Novartis, GlaxoSmithKline, and Eli Lilly agreed to overhaul themselves in a series of deals totaling $28.5 billion. Also, Valeant Pharmaceuticals International made a hostile $45.7 billion bid for Botox maker Allergan supported by Allergan’s largest shareholder, investor William Ackman’s Pershing Square Capital Management.